Table 3.
Impact of hydroxyurea and phlebotomy on pain events requiring acute care
| Pre‐HU |
On HU at MTD |
On HU and phlebotomy |
||||
|---|---|---|---|---|---|---|
| Patient # | Pain events/yr | Years observed | Pain events/yr | Years observed | Pain events/yr | Years observed |
| 1 | 6 | 3 | 1.5 | 4 | n/a | n/a |
| 5 | 3 | 3 | 0 | 4 | n/a | n/a |
| 6 | 3 | 4 | 3 | 2 | 0 | 2 |
| 7 | 2 | 5 | 0 | 3 | n/a | n/a |
| 8 | 2 | 3 | 2 | 4 | n/a | n/a |
| 10 | 2.5 | 2 | 4 | 3 | 4 | 1 |
| 11 | 1 | 2 | 1 | 1 | 0 | 1 |
| 12 | 2 | 3 | 0.5 | 6 | n/a | n/a |
| 14 | 1 | 4 | 0 | 1 | n/a | n/a |
Table includes all patients placed on hydroxyurea for pain events with documented achievement of MTD. Patient 6 was lost to follow‐up after two years of monthly phlebotomy; during that year off dual therapy, acute care usage for pain events returned to 3 per year.